Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

ECM Weekly (1 December 2018) - Softbank Corp, Tencent Music, Cansino, Wuxi Apptec, Fosun Tourism

Fosun Tourism IPO - Fair Value Is Probably Below Low-End

AsiaInfo Tech (亚信科技) IPO: Latest Numbers Showcase the Company's Questionable Expansion Plan

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Yestar Aesthetic Medical / Equity Capital Markets

<p>Yestar, a leading aesthetic medical chain in China, is seeking to list in Hong Kong. In this insight, we will cover the following topics:</p>
<ul>
<li>The business lines of the company</li>
<li>Growth drivers</li>
<li>Risk of the business</li>
<li>Company history and shareholders</li>
<li>Initial thoughts on valuation</li>
</ul>
<p>We have seen red flags that we would simply pass the deal.</p>

Yestar, a leading aesthetic medical chain in China, is seeking to list in Hong Kong. In this insight, we will cover the following topics:

The business lines of the company
Growth drivers
Risk of the business
Company history and shareholders
Initial thoughts on valuation

We have seen red flags that we would simply pass the deal.

Yestar Aesthetic Medical (艺星医疗) IPO: Founders' Origin and Red Flags Matter